JP2019501130A - トリアゾールリンカーを有するヘテロ二官能性の汎セレクチン拮抗剤 - Google Patents

トリアゾールリンカーを有するヘテロ二官能性の汎セレクチン拮抗剤 Download PDF

Info

Publication number
JP2019501130A
JP2019501130A JP2018526565A JP2018526565A JP2019501130A JP 2019501130 A JP2019501130 A JP 2019501130A JP 2018526565 A JP2018526565 A JP 2018526565A JP 2018526565 A JP2018526565 A JP 2018526565A JP 2019501130 A JP2019501130 A JP 2019501130A
Authority
JP
Japan
Prior art keywords
compound according
alkyl
compound
selectin
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018526565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501130A5 (enExample
Inventor
ビート アーンスト，
ビート アーンスト，
ベアトリス ワーグナー，
ベアトリス ワーグナー，
Original Assignee
グリコミメティクス， インコーポレイテッド
グリコミメティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリコミメティクス， インコーポレイテッド, グリコミメティクス， インコーポレイテッド filed Critical グリコミメティクス， インコーポレイテッド
Publication of JP2019501130A publication Critical patent/JP2019501130A/ja
Publication of JP2019501130A5 publication Critical patent/JP2019501130A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2018526565A 2015-12-02 2016-11-30 トリアゾールリンカーを有するヘテロ二官能性の汎セレクチン拮抗剤 Pending JP2019501130A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262155P 2015-12-02 2015-12-02
US62/262,155 2015-12-02
PCT/US2016/064189 WO2017095904A1 (en) 2015-12-02 2016-11-30 Heterobifunctional pan-selectin antagonists having a triazole linker

Publications (2)

Publication Number Publication Date
JP2019501130A true JP2019501130A (ja) 2019-01-17
JP2019501130A5 JP2019501130A5 (enExample) 2020-01-09

Family

ID=57681725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526565A Pending JP2019501130A (ja) 2015-12-02 2016-11-30 トリアゾールリンカーを有するヘテロ二官能性の汎セレクチン拮抗剤

Country Status (5)

Country Link
US (1) US20200171005A9 (enExample)
EP (1) EP3383882A1 (enExample)
JP (1) JP2019501130A (enExample)
CA (1) CA2950088A1 (enExample)
WO (1) WO2017095904A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022546277A (ja) * 2019-08-20 2022-11-04 グリコミメティクス， インコーポレイテッド Ｅセレクチン阻害剤中間体を調製するためのプロセス

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519181B2 (en) 2014-12-03 2019-12-31 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
CN117298287A (zh) 2016-10-07 2023-12-29 糖模拟物有限公司 高效的多聚体e-选择蛋白拮抗剂
WO2018169853A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
JP7275131B2 (ja) 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
WO2019133878A1 (en) * 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
WO2019173229A1 (en) 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
US20220220144A1 (en) * 2019-04-24 2022-07-14 Glycomimetics, Inc. Multimeric pan-selectin antagonists
WO2021195465A1 (en) 2020-03-27 2021-09-30 Magnani John L Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectin
JP2023527411A (ja) 2020-05-31 2023-06-28 グリコミメティクス， インコーポレイテッド がん細胞の負荷を減少させ、正常な造血を保護するための化合物および方法
AU2021292458A1 (en) 2020-06-14 2023-01-19 GlycoMimetics Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting
US20240269157A1 (en) 2021-08-03 2024-08-15 Glycomimetics, Inc. Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058304A1 (en) * 2002-12-20 2004-07-15 Glycomimetics, Inc. Oligosaccharides and conjugates thereof for the treatement of pseudomonas bacteria infection
JP2009507031A (ja) * 2005-09-02 2009-02-19 グリコミメティクス， インコーポレイテッド ヘテロ二官能性全セレクチン阻害剤
WO2009126556A1 (en) * 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
WO2012037034A1 (en) * 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058304A1 (en) * 2002-12-20 2004-07-15 Glycomimetics, Inc. Oligosaccharides and conjugates thereof for the treatement of pseudomonas bacteria infection
JP2009507031A (ja) * 2005-09-02 2009-02-19 グリコミメティクス， インコーポレイテッド ヘテロ二官能性全セレクチン阻害剤
WO2009126556A1 (en) * 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
WO2012037034A1 (en) * 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022546277A (ja) * 2019-08-20 2022-11-04 グリコミメティクス， インコーポレイテッド Ｅセレクチン阻害剤中間体を調製するためのプロセス

Also Published As

Publication number Publication date
US20180369205A1 (en) 2018-12-27
EP3383882A1 (en) 2018-10-10
CA2950088A1 (en) 2017-06-02
US20200171005A9 (en) 2020-06-04
WO2017095904A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
JP2019501130A (ja) トリアゾールリンカーを有するヘテロ二官能性の汎セレクチン拮抗剤
KR102653723B1 (ko) 매우 강력한 다량체성 e-셀렉틴 길항물질
JP6689854B2 (ja) Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
US20150284420A1 (en) E-selectin antagonist compounds and methods of use
CA3054605A1 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
US20170296566A9 (en) Methods and compositions for treating and/or preventing mucositis
CN111566117A (zh) E-选择蛋白和半乳凝素-3的异双功能抑制剂
WO2020219419A1 (en) Multimeric pan–selectin antagonists
WO2016164394A1 (en) 2-halo-galactose-containing selectin antagonists
KR20220012246A (ko) E-셀렉틴, 갈렉틴-3, 및/또는 cxcr4 케모카인 수용체의 갈락토오스 연결된 다량체성 글리코모방체 억제제
WO2000053190A1 (fr) Nouveaux immunodepresseurs
WO2021222767A1 (en) Cd33 ligands suitable for incorporation into carriers
WO2021222777A1 (en) Cd33 ligands suitable for incorporation into carriers
EP1405640A1 (en) Novel immunosuppressants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180720

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20180720

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200714

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210302